8,000 שקל לחפיסה: התקווה החדשה לחולי סכיזופרניה רחוקה מהישג ידם

הערכה

A new schizophrenia drug with a novel mechanism of action has entered the Israeli market at 8,000 shekels per pack, placing it out of reach for most patients. The price tag means access depends entirely on inclusion in the national health basket, a bureaucratic process that moves slowly. One patient advocate states plainly that families simply cannot buy it if it stays outside the basket. The immediate question is whether the Health Ministry will prioritize this drug in the next basket update, and how many patients will wait in the meantime.